Drugs / RSV vaccine candidate formulation 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05639894 | Nov 2022 → May 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV vaccine candidate formulation 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639894 ↗ |
| Modality | Vaccine | “RSV vaccine candidate” NCT05639894 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular injection” NCT05639894 ↗ |